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LifeTime aims to track, understand and target human cells during the onset and 
progression of complex diseases and their response to therapy at single-cell 
resolution. This mission will be implemented through the development and 
integration of single-cell multi-omics and imaging, artificial intelligence and 
patient-derived experimental disease models during progression from health to 
disease. Analysis of such large molecular and clinical datasets will discover molecular 
mechanisms, create predictive computational models of disease progression, and 
reveal new drug targets and therapies. Timely detection and interception of disease 
embedded in an ethical and patient-centered vision will be achieved through 
interactions across academia, hospitals, patient-associations, health data 
management systems and industry. Applying this strategy to key medical challenges 
in cancer, neurological, infectious, chronic inflammatory and cardiovascular 
diseases at the single-cell level will usher in cell-based interceptive medicine in 
Europe over the next decade.
While advances in medicine have led to spectacular progress in certain 
disease areas, most chronic disorders still partially or totally escape 
cure. This is mainly because most diseases are only detected late once 
gross physiological symptoms manifest themselves, when tissues and 
organs have often undergone extensive or irreversible changes. At this 
stage, the choice of interventions is typically quite limited. It is difficult 
to predict if a patient will respond to a particular treatment, which often 
involve invasive or aggressive therapies that can be of modest benefit, 
or if therapy resistance emerges leading to relapse. The reason for this 
is that despite technology-driven revolutions that enable a patient’s 
physiology to be investigated at the level of molecules1,2 and placed 
in the context of tissues3,4 in most cases our detection and predictive 
power is limited by our incomplete mechanistic understanding of dis-
ease at the cellular level.
Cells develop and differentiate along specific lineage trajectories 
forming functionally distinct cell types and states5, which together 
with their neighbouring cells underlie and control normal physiol-
ogy (Fig 1). However, we have not been able to systematically detect 
and understand the molecular changes that propel an individual cell 
along these trajectories during normal development or ageing nor the 
molecular causes that trigger deviations from healthy trajectories and 
drive cells and tissues towards disease (Fig 1). Timely detection and 
successful treatment of disease will depend crucially on our ability to 
understand and identify when, why, and how cells deviate from their 
normal trajectory. More accurate cellular and molecular diagnostics 
will enable us to intercept disease sufficiently early to prevent irrepa-
rable damage. To achieve this interceptive medicine (Fig 1), we need to 
invest in approaches that provide a detailed molecular understanding 
of the basis of disease heterogeneity in tissues, with sufficient molecu-
lar, cellular and temporal resolution.
Several challenges need to be overcome to reveal the complex dis-
ease landscapes comprised of vast numbers of potential cellular states 
(Fig 1). Firstly, we need to resolve normal cellular heterogeneity across 
space and time to begin to determine the cell types, states and cell-cell 
interactions in the body. This is a main goal of the Human Cell Atlas 
consortium6. However, to discover the cellular basis of diseases requires 
that we track cellular heterogeneity and molecular composition of cell 
trajectories in health and during disease progression longitudinally - 
throughout a patient’s lifetime (“LifeTime”). Secondly, we need to under-
stand the molecular mechanisms and complex networks that define a 
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cell’s state, and control its function, fate and trajectory over time to be 
able to reconstruct a cell’s history and predict its future. This is essential 
for selecting the optimal intervention for an individual patient. Thus 
systematic and longitudinal profiling of samples from many patients is 
required. Third, computational frameworks for integrating temporal 
data as well as patient profiles with large cohorts to identify regulatory 
changes and to dissect the causes and manifestations of disease remain 
elusive. Current attempts to model human disease have not succeeded 
in integrating the thousands of molecular phenotypes that are acquired 
from patients. Finally, we are limited by our lack of knowledge of the 
underlying causes of disease. Any given patient’s response to a specific 
therapy may require testing or modifying cells from the patient in an 
experimental system, a challenge yet to be routinely implemented.
To address these challenges experts from different disciplines came 
together in 2018 to form the LifeTime Initiative (https://www.lifetime-
initiative.eu). It has since grown to be a pan-European community 
consisting of over 90 research institutions with the support from 80 
companies, several funding agencies and national science academies. 
In 2019 the initiative was awarded a Coordination and Support Action 
by the European Commission to develop a Strategic Research Agenda 
(SRA)7 for a large-scale long-term initiative with a roadmap for imple-
menting cell-based and interceptive medicine in Europe in the next 
decade. The ambitious goal is the early detection and interception 
of complex diseases as well as being able to select the most effective 
therapeutic strategy for a patient. Between March 2019 to June 2020 
the initiative established several multi-disciplinary working groups 
(listed in supplementary information), organised numerous work-
shops, meetings and surveys (and thus engaged the wider community) 
and commissioned stakeholder interviews and an impact study. The 
European Commission will use LifeTime’s SRA during the planning of 
the next research and innovation framework programme - Horizon 
Europe. Here, we outline LifeTime’s vision and key aspects of the SRA 
towards establishing cell-based interceptive medicine.
Central to LifeTime’s vision and approach is the development and 
integration of novel technologies, such as single-cell multi-omics and 
high-content imaging, artificial intelligence (AI) and patient-derived 
experimental disease models. Applying these integrated approaches to 
address medical challenges and incorporating them in both experimen-
tal and clinical workflows is expected to directly benefit patients. For 
example, appropriate single-cell based biomarkers will precociously 
alert physicians that a cell or tissue is entering a disease trajectory. 
Understanding disease heterogeneity at the cellular level and knowing 
the molecular aetiology of a disease will allow the systematic identifi-
cation of drug targets, resistance mechanisms or define therapeutic 
approaches, based on a given disease’s molecular or cellular vulner-
ability. This strategy differs significantly from the classical approaches 
in drug discovery8. The stratification of patients based on underlying 
disease mechanisms, assessed in situ within single cells, will help physi-
cians select the most appropriate treatment(s) or employ combination 
therapies that are tailored to the individual. These will be used first to 
identify cells that are deviating from the healthy trajectory, to steer 
them away from disease, and later to reduce the threat of relapse (Fig 1). 
This transformative single-cell data-driven approach has the potential 
to increase the success rates of clinical trials as well as the efficiency of 
novel therapeutic interventions in clinics over the next decade. Overall, 
the LifeTime strategy is likely to impact both diagnosis and treatment, 
improve health and quality of life dramatically and alleviate the soci-
etal burden of human diseases such as cancer, neurological disorders, 
infectious diseases, chronic inflammatory and cardiovascular diseases.
Below, we outline the technology development and implementation 
at the heart of LifeTime’s approach, describe LifeTime’s mechanism to 
identify medical priorities, discuss required infrastructures in Europe, 
interactions with industry and innovation, ethical and legal issues, 
LifeTime’s education and training vision, and estimate the expected 
impact of the LifeTime approach on medicine and healthcare. LifeTime 
builds on and will collaborate with related international initiatives that 
are paving the way by producing reference maps of healthy tissues in 
the body, such as the Human Cell Atlas (HCA)6 and the NIH Human 
Biomolecular Atlas Program (HuBMAP)9.
Technology development and integration
Single-cell technologies, particularly transcriptomics, are generating 
the first reference cell atlases of healthy tissues and organs, revealing a 
previously hidden diversity of cell subtypes and functionally distinct 
cell states6. Single-cell analyses of patient samples are beginning to 
provide snap-shots of the changes in cell composition and pathways 
associated with diseases including cancer10–15, chronic inflammatory 
diseases16,17, Alzheimer’s disease18–20 heart failure21, and sepsis22. Since 
pathophysiological processes within individual cells involve different 
molecular levels, understanding the underlying mechanisms requires 
the integration of current single-cell approaches. LifeTime proposes the 
integration of several approaches7. This includes combining transcrip-
tomics (Fig. 2) with methodologies that provide additional information 
on chromatin accessibility, DNA methylation, histone modifications, 
3D genome organisation, and genomic mutations23–25. Future develop-
ments will enable the incorporation of single-cell proteomes, lipidomes, 
and metabolomes, adding crucial insight into different cellular states 
and their roles in health and disease. In addition to specific cell subtypes 
and the role of cellular heterogeneity, investigating the surrounding 
tissue context and organ environment is crucial. New spatial -omic 
approaches, particularly spatial transcriptomics, include information 
on the location of diseased cells, their molecular makeup and aberrant 
cell-cell communication within the tissue26–32. Novel advanced imaging 
approaches also now enable systematic spatial mapping of molecular 
components, in situ, within cells and cells within tissues28,33–37. The cel-
lular context with respect to different immune and stromal cell types, 
extracellular components and signaling molecules that contribute to 
disease progression will help identify the roles of specific cell types 
and interactions in diseases32,38–40. The implementation of cell lineage 
tracing approaches41, which link cellular genealogies with phenotypic 
information of the same cells, may help us understand how popula-
tions of cells develop dynamically to form the specific architecture of 
a healthy or a diseased tissue.
LifeTime proposes to develop necessary single-cell methodologies 
and end-to-end pipelines (Fig 2) that will be integrated into robust, 
standardised multi-omics and imaging approaches, and scaled to 
profile hundreds of thousands of patients’ cells7. This will require 
an in-depth analysis of longitudinal human samples obtained from 
patients and cohorts, including European and national clinical trial 
groups as well as initiatives collecting longitudinal biological material 
connected to well-annotated clinical information (Fig 3). Linking these 
data to clinical outcomes will identify the cellular parameters that are 
permissive to a therapeutic response, for example during checkpoint 
blockade immunotherapy12,42,43 or treatment of multiple myeloma11. By 
detecting rare drug resistant cells that are present prior to11,44 or that 
emerge during treatment45, therapeutic regimens and combinatorial 
treatments can be adapted to improve outcome.
Handling these large molecular datasets will require sophisticated 
and distributed computational and bioinformatics infrastructures, 
(see Implementation and Infrastructure), as well as the development 
of tools to integrate and ensure interoperability of different data types, 
including single-cell multi-omics, medical information and electronic 
health records. LifeTime will work with ongoing European and national 
efforts for integrating molecular data into electronic health records and 
to establish standards and interoperable formats to address specific 
disease challenges. This will promote the development of advanced 
personalised models of disease. To be able to implement routine lon-
gitudinal sampling of patients approaches need to be developed for 
sampling small biopsies, including liquid biopsies, that will detect 
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individual cells or cell-free DNA released from pathological cells before 
and during therapy46. Multi-dimensional descriptors of cell states from 
patients taken from different stages of disease or therapy will be used 
to derive new biomarker sets or enhance current panels. Collaboration 
with ongoing atlas projects, industrial partners and regulatory authori-
ties, will be key for benchmarking and deriving the new standards that 
will enable us to deploy these new methods in the clinic. This will hope-
fully achieve earlier disease detection and guide the appropriate selec-
tion of drug targets and therapies (Fig 3).
Unlocking the potential of unprecedented amounts of integrated 
digital information (including molecular data describing how indi-
vidual cells make decisions) requires AI, in particular machine learn-
ing approaches that can identify meaningful molecular patterns and 
dependencies in the datasets47,48. Although such approaches have 
proven very useful when applied to medical imaging data and have 
enabled the identification of subtle disease-associated changes49, medi-
cal imaging cannot capture the full complexity of human physiology nor 
the status of the disease at the single-cell level. High-content imaging, 
together with gene expression profiling, chromatin states, protein and 
metabolic parameters will contribute to the stratification of disease 
phenotypes. Machine learning and advanced modelling approaches will 
be used to integrate and analyse the different layers of cellular activity, 
and can generate multi-scale and potentially even causal models that 
will allow us to infer regulatory networks and predict present and future 
disease phenotypes at the cellular level47,50–52 (Fig 2).
The deep integration of machine learning technologies with spa-
tial multi-omics and imaging technologies and data has the potential 
to usher in a new age of digital pathology to aid the decision-making 
process of physicians (Fig 3). By considering not only anatomical, 
physiological and morphological aspects, but also multidimensional 
molecular and cellular data, it will be possible to provide a more 
granular representation of a patient’s disease state to complement 
the pathologist’s slides and bulk measurements in tissues (e.g. mRNA, 
metabolites). We envision as the final goal the incorporation of new 
AI-based decision-aiding systems that will integrate and interpret avail-
able molecular, cellular, individual disease trajectory and imaging 
information. Importantly, interpretable and accountable AI systems 
will also provide the basis for clinical recommendations. Integration 
of cellular information should lead to a more precise description of 
a patient’s molecular and physiological history, and will guide early 
detection, allow predictive prognosis, and guide recommendations 
for therapeutic interventions to deliver more precise and effective 
treatments (Fig 3).
Understanding the cellular origin and aetiology of disease from a 
patient-centered perspective requires systems that faithfully recapitu-
late key aspects of a patient’s pathophysiology, and render them experi-
mentally tractable to test mechanistic hypotheses and predictions. 
Organoids are an emerging experimental system that allow modelling 
aspects of organ development, regeneration and pathophysiology3,4,53 
(Fig 2). Derived from adult or pluripotent human stem cells, organoids 
can capture individual features that are unique to each patient and 
can be interrogated molecularly in space and time. Importantly, by 
comparing organoid models from diseased and healthy individuals, 
unique disease features can be extracted even without knowing the 
specific genetic cause of the disease. Therefore, organoid models 
offer a unique tool for achieving some of the main goals of LifeTime, 
especially in cases where repeated access to patient tissues is limited 
or impossible, for instance for neurological disorders.
Despite their promise organoids still require significant development 
to harness their full potential for disease modelling (Fig. 2). LifeTime 
proposes to advance the models to capture the full degree of cellular 
heterogeneity, tissue-specific structural and metabolic conditions54, 
incorporation of key physiological aspects, such as immune response, 
vascularisation or innervation. Because complex interactions between 
multiple tissues and organs are involved in many diseases, it will be 
necessary to develop novel tissue engineering principles that com-
bine multiple organoids in pathophysiologically relevant crosstalk 
(organoid-on-a-chip). To optimise translational potential, LifeTime will 
engage in standardising, automating and scaling organoid approaches, 
allowing for systematic derivation, propagation and banking. Such 
industrialisation is also needed for large scale chemical or genetic 
perturbations (e.g. CRISPR-Cas screens), and for elucidating the genetic 
basis for disease variability and drug response at population-relevant 
scales, in both the preclinical and clinical context (Fig 3). The result-
ing mechanistic dissection enabled by large-scale perturbations will 
be used to validate corresponding AI models of disease interception 
and progression.
In addition to organoids, in vivo model systems are necessary to trans-
late the science from bench to humans. A complex biological system 
is required to study the myriad of host-disease and pathogen interac-
tions associated with complex diseases, such as infectious diseases, 
cancer or Alzheimer’s disease. The use of animal models is important 
for understanding the very complex temporal relationships that occur 
in disease such as those involving the vasculature, immune system 
and pathogens as well as neuronal networks in the brain. LifeTime will 
therefore improve their clinical relevance and make use of models in 
which patient-derived tissues can be integrated into in vivo models55–59 
to study dynamics of cellular heterogeneity in space and time.
LifeTime, as a community, has the capacity to develop and inte-
grate these technologies, that often require expertise and specialised 
instrumentation located in distinct laboratories. A coordinated effort 
can achieve the required benchmarking and standardisation of tech-
nologies, workflows and pipelines. This will also ensure that the data, 
software and models generated adhere to Findable, Accessible, Inter-
operable, and Reusable (FAIR) principles60 (see infrastructure below), 
are available across national borders, and are in full compliance with 
international legislations such as the European General Data Protection 
Regulation (GDPR). Moreover, LifeTime will ensure that technologies, 
including AI and organoids, will be developed in an ethically responsible 
way in collaboration with patients, putting the patient at the centre. 
(see Ethical and Legal Issues).
LifeTime disease Launchpad to identify medical 
priorities
LifeTime has initiated a mechanism, called Launchpad, to system-
atically identify medical challenges that can be addressed through 
LifeTime’s approach and have a direct impact on patient care. Initially, 
the focus has been on five disease areas that are a significant burden to 
society: cancer, neurological disorders, infectious diseases, chronic 
inflammatory diseases as well as cardiovascular diseases. Importantly, 
other disease areas will be continuously monitored, for example rare 
Mendelian diseases and metabolic diseases, and research programmes 
initiated as technologies and infrastructures develop. The LifeTime 
Launchpad has defined several criteria to identify the medical chal-
lenges. These include: societal impact (including incidence and preva-
lence, disease severity, economic impact and the pressing need for new 
and more efficient clinical treatments and early detection), evidence 
for cellular heterogeneity that limits current clinical avenues, avail-
ability of samples from biobanks, relevant preclinical models, exist-
ence of patient cohorts including those enabling longitudinal studies, 
clinical feasibility and ethical considerations, as well as alignment with 
national and EU funding priorities. Subsequently, multidisciplinary 
working groups, including clinicians, in each disease area have used 
these criteria to define the following disease challenges and develop 
ten-year roadmaps to address them in the LifeTime Strategic Research 
Agenda7.
Despite cancer broadly covering hundreds of individual tumour 
types, there are critical knowledge gaps that are common for all can-
cer entities, including early dissemination and therapy resistance. 
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Metastatic dissemination of a subpopulation of cancer cells is a lead-
ing cause of death in almost all cancer types. Successful treatment of 
advanced and metastasised forms of cancer remains difficult, despite 
the development of targeted therapies and immunotherapies, due to 
the emergence of drug or therapy resistance. To address these medical 
priorities LifeTime recommends focusing on understanding the cell 
types and states - malignant cells and their microenvironment - involved 
in early stages of cancer dissemination and the reprogramming of 
cellular states during disease and their impact on therapy resistance.
For neurological disorders a major challenge is a lack of understand-
ing of the early events in disease onset to enable the development of 
disease modifying therapies. The lack of access to longitudinal samples 
from patients requires the establishment of cohorts of patient-derived 
disease models to understand the cellular heterogeneity associated 
with disease. Discovering pathways and biomarkers for the stratifica-
tion of patients based on the cellular mechanisms driving the disease 
will enable new design of clinical trials to reevaluate drugs previously 
tested without such stratification and broaden the drug target portfolio.
As seen during the COVID-19 pandemic it is important to be able to 
understand infection mechanisms and the host response to rapidly 
identify the most likely effective treatment. At the same time the con-
tinuous rise of antimicrobial resistance requires the discovery of novel 
therapeutic strategies. A key medical challenge for infectious diseases 
is to understand the cellular response to infections and develop novel 
precision immune-based therapeutic strategies to combat infections.
The high burden of chronic inflammatory diseases is due to long-term 
debilitating consequences resulting from structural destruction of 
affected organs or tissue. Current therapies only treat the symptoms 
and do not cure or fully control the chronic inflammatory patho-
physiology. While many different targeted therapies exist, they are 
expensive and are limited by high rates of non-response to treatment. 
Consequently, there is an urgent need to explore and understand how 
cellular heterogeneity contributes to the pathology of inflammatory 
diseases61,62 and how this relates to the predicted course of disease 
and response of a patient to one of the numerous available therapies.
Many cardiovascular and metabolic diseases lack effective therapies 
due to a lack of knowledge of the underlying causes and the link between 
abnormal cardiac cell structure/function and pathophysiology. The 
identified medical priority is to understand cellular and molecular 
mechanisms involved to enable early diagnosis and to design new 
mechanism-based therapies for precise clinical treatment.
The LifeTime disease roadmaps can be divided broadly into three 
phases7: firstly, immediate research into the identified medical chal-
lenges using established, scaled single-cell technologies, computa-
tional tools and disease models; secondly, the development of new 
technologies required to address specific medical challenges, including 
the development of spatial- multi-omics and imaging approaches and 
advanced patient-derived model systems for longitudinal analyses; 
finally, applying these next-generation technologies for longitudinal 
analyses of patient samples, or patient-derived models, combined 
with machine learning to generate patient trajectories and predictive 
models of disease. Resulting predictions and biomarkers would be 
validated in prospectively collected patient cohorts within clinical 
trials also including longitudinal liquid biopsies. The routine clinical 
use of predictors and biomarkers for risk stratification of patients 
and resulting interventions - where feasible - is the pre-final step. The 
final step is the extension of predictors and biomarkers to the analy-
sis of large longitudinal patient cohorts such as national cohorts for 
developing secondary and tertiary prevention approaches based on 
the new biomarkers.
During implementation of these roadmaps the initiative will establish 
an experimental design working group to develop systematic pro-
cedures to ensure that the research samples acquired cover diverse 
subjects including age, sex-and-gender-in-research dimension and 
ethnicity. This will require the development of strict criteria for the 
inclusion of samples and ensure appropriate coverage of critical meta-
data. They will also define standardised procedures for acquiring and 
processing of samples from different pathology sites (depending on 
the disease area). It is envisaged that during disease challenge pilot 
projects an experimental design oversight body will determine, based 
on early data, the number of diseases that should be studied as the 
initiative develops with recommendations on appropriate sample 
sizes required to obtain sufficient statistical power.
Implementation and Infrastructure
The scale of the data that will be generated and analysed, the 
cross-disciplinary and international structure combined with the 
ambition of LifeTime to pioneer novel analytics using AI, places Life-
Time in an excellent position to shape the next generation of European 
medical and biological data computational infrastructure. This will 
require close interaction with and evolution of the established Euro-
pean infrastructure (Fig 4), such as the European Open Science Cloud 
(EOSC) and high-performance computing infrastructures through 
EuroHPC. LifeTime will also interact with related European Life Sciences 
Research Infrastructures63 to create added value and to avoid duplica-
tion of efforts in strategies and tools for sharing and accessing data, 
development and application of standards. As medicine is inherently 
decentralised, LifeTime will also contribute to connecting EU medical 
systems and large centralised European data infrastructures.
Fragmentation of research across borders, disciplines and time-
frames needs to be overcome. LifeTime data generation and technology 
development will be harmonised across expert groups and centres, 
allowing results to be quickly applied in clinics. Thus, a coordinated 
approach is required that integrates the multidisciplinary expertise of 
single-cell technologies, data science, and organoids/in-vivo models 
across Europe. It must also engage clinicians and patients to achieve 
medical impact. To address these challenges, LifeTime proposes a 
multidisciplinary network of LifeTime Centres (Fig 4) with different 
complementary thematic clusters across Europe, each working in 
close association with hospitals. These connected, flexible innova-
tion nodes will share resources, gather the necessary critical mass for 
global competitiveness, and be open for collaboration with the entire 
scientific community. Importantly, LifeTime Centres should deliver a 
number of key functions:
•	 Serve as platforms for the development and advancement of break-
through technologies for single-cell research in omics and imag-
ing, AI/machine learning and experimental/computational disease 
models.
•	 Closely and actively collaborate with patients, clinicians, hospitals 
and healthcare systems, in some cases with a specific disease focus.
•	 Set standards in data generation, standardisation and management 
implementing FAIR principles.
•	 Set standards in ELSI programmes (ethical, legal and societal issues) 
by working together in multidisciplinary teams aimed at responsible 
research and innovation.
•	 Offer opportunities to collaborate, test and benchmark new method-
ologies and analysis methods e.g. in adaptive experimental design.
•	 Offer unique opportunities to industry to translate recent knowledge 
and novel technologies from the laboratory to the market.
•	 Provide an early access programme to new technologies developed 
by companies.
•	 Function as open, interconnected education hubs, delivering train-
ing in the new technologies to researchers, scientific personnel and 
clinicians, as well as provide engagement activities for patients and 
citizens.
LifeTime aims to analyse data which is inherently distributed across 
different clinical centres in different countries, which is a significant 
challenge. These data are usually not accessible outside a national, 
regional clinical care system or specified data ‘safe havens’, when they 
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are accessible accredited systems are often required for storing the 
data and information governance may be at the hospital, federal or 
international level. This means that a federated approach is the only way 
to access and integrate information from various European healthcare 
systems. Thus, the LifeTime data and computational network building 
on cloud technologies will provide the necessary capacities to enable 
federated analytics across the LifeTime centres and will provide a tech-
nical and legal framework for integrating core information structures, 
multi-omics assays, imaging, AI/machine learning technologies and 
health records (Fig 4). A joint Data Coordination Centre following a 
multi-level approach will ensure transparent data access control, com-
patibility and standardisation. Within this framework LifeTime will also 
coordinate and pioneer open data sharing and reuse and collaboration, 
including access models prior to publication of data.
To start this cooperative LifeTime Centre network, the initiative can 
build on first initiatives by LifeTime members in a number of European 
countries, examples are the VIB Single-cell Accelerator Programme in 
Belgium, the Berlin Cell Hospital/Clinical Single-cell focus in Germany, 
the UK’s Sanger/EBI/Babraham Single Cell Genomics Centre, or the 
LifeTime Single-Cell Centre in Poland, to name a few. To avoid dupli-
cation and lack of standardisation, the LifeTime Cell Centre network 
should be coordinated through an entity or framework that optimises 
coordination and support to achieve the LifeTime vision. Funding for 
specific research projects that involve one or more LifeTime Centres 
could come from a portfolio of private and public funding opportu-
nities, both on the national and pan-European level. The network will 
closely interact with key European efforts and will contribute to EU 
strategies and programmes.
Interaction with industry/innovation framework
Collaborations with the private sector will be key for rapid translation 
and delivery of technologies, instrumentation, diagnostics and thera-
pies (Fig 4). Currently over 80 companies support LifeTime’s vision. 
These span multiple sectors as well as industrial associations and net-
works such as the European Federation of Pharmaceutical Industries 
(EFPIA), and the Euro-BioImaging Industry Board (EBIB).
Transforming breakthrough discoveries into solutions to improve 
the health of European citizens involve several crucial steps. These 
include creating a unifying framework that fosters and streamlines 
pre-competitive interactions between academia and industry at the 
interface of computer science, single-cell biology, -omics, imaging, 
patient-derived disease modelling and precision medicine. A large-scale 
collaboration platform across Europe should be developed that pro-
vides umbrella agreements, regular physical meetings, dual training 
of early-career scientists in academia and industry, as well as exchange 
programmes. This will enable joint projects between public and private 
sectors spanning the entire biomedical innovation cycle from discovery 
research, technology development and implementation in hospitals 
and the healthcare industry.
Cross-sectoral collaborations between small, medium-size and large 
companies with different development timelines and distinct business 
models is crucial to stimulate innovation. To expedite the identification 
of, and investment in the emerging technologies developed in academic 
and industry laboratories, successful local initiatives such as tech watch 
and accelerator programmes (e.g. the VIB Single-cell Accelerator) should 
be scaled and coordinated at the EU level. LifeTime aims to create a 
networking/match-making platform for individuals, academic and 
industry organisations that share the goal of developing and integrating 
breakthrough technologies and applying them in the clinic to benefit 
patients. Further measures could foster innovation and entrepreneur-
ship. For example, a pre-seed, pre-incubator funding scheme based on 
competitive calls to support start-up or tech transfer ideas.
Creating a dedicated European ecosystem is also essential. Achiev-
ing this requires additional key measures such as the development of 
enabling digital environments, promotion of early disease interception 
with all necessary stakeholders (patients, regulators, payers, etc.) as 
described in the LifeTime call for action launched in December 2019 
(https://lifetime-initiative.eu/make-eu-health-research-count/).
Ethical and Legal Issues
The implementation of LifeTime’s vision triggers relevant ethical 
questions from all societal groups directly impacted by the project 
(patients, clinicians and scientists), and society in general. LifeTime 
aims to pioneer a real-time or parallel ELSI (ethical, legal and societal 
issues) programme that will predict, identify, monitor and manage the 
ethical impact of the biomedical innovations that arise from research 
and technology development, ensuring that implementation follows 
ethical guidelines. LifeTime’s ELSI programme can be used as a test-
ing ground for other international interdisciplinary initiatives (Fig 4). 
Ethical issues will be identified and managed as early as possible and 
ensure that ethical and research integrity guidance is implemented 
throughout the entire research process to stimulate positive effects 
and mitigate negative ones64.
Specialists in bioethics, public engagement, ethics of technology and 
lawyers have identified LifeTime’s ethical and societal priority areas. 
These include questions related to the derivation, storage and use of 
organoids, the use of AI, data ownership and management, anonymisa-
tion of data, equity of access to such revolutionary medical care, the 
definition of health and illness, and transparent science communi-
cation to society65. Initiating a relationship of trust with citizens will 
include diverse modes of communication and engagement, for example 
through art, citizen science and public dialogue, contributing to sci-
entific literacy, and promoting individual critical thinking and public 
participation in decision-making processes.
Education and Training
Introducing interceptive medicine into clinical practice in parallel with 
a multidisciplinary research programme will require capacity building 
in health and research systems, and significant technology deploy-
ment in the clinics. This will lead to a collaborative, fast-developing and 
interdisciplinary environment in research and in the clinics, requiring 
new training inputs. To respond to these needs, LifeTime will create an 
Education and Training Programme, ensuring the sustainable appli-
cation of new technologies and implementation of new medical and 
scientific approaches (Fig 4). Importantly, this will be done in an integra-
tive scheme, intersecting the multiple LifeTime disciplines and areas of 
actions: disruptive technologies applied to medical challenges, technol-
ogy transfer and innovation, research integrity, data management and 
stewardship, ethical and societal issues, communication and emotional 
skills, or management of medico-scientific and collaborative projects.
Each LifeTime training activity will be based on multi-lateral edu-
cation: basic researchers will teach other researchers and clinicians 
about the potential of the technological solutions, while clinicians will 
teach researchers about clinical needs and biological challenges of the 
diseases in focus. This will strictly follow the idea of bench to bedside 
and back. The programme will have an inclusive philosophy to ensure 
that it can provide training to the wide community, including research-
ers, clinicians, technical operators, managers and staff of technology 
platforms, as well as administrators, patients and the lay public.
LifeTime envisions the organization of cycles of colloquia and outreach 
activities to inform the public, the formulation of short-term courses 
compatible with a culture of lifelong learning and adaptability, as well 
as interdisciplinary Masters and PhD programmes. Through education 
and training, LifeTime will engage and inform society, will develop new 
professional curricula and will train a new generation of highly skilled 
medical scientists and support staff, in order to foster scientific and 
medical excellence in an ethical, responsible and inclusive framework.
Nature | www.nature.com | 5
AC
CE
LE
RA
TE
D  
AR
TI
CL
E  
PR
EV
I E
W  
AC
CE
LE
RA
TE
D  
AR
TI
CL
E  
PR
EV
I E
W  
Impact on Medicine and Healthcare
Medicine and healthcare are rapidly expanding pillars of our economy. 
EU countries collectively spend more than €1,400 billion per year on 
healthcare for their 500 million citizens. Given the dimensions and 
spiraling healthcare costs associated with an ageing population, these 
numbers will continue to increase unless we can mitigate the damaging 
effects of ageing. We expect that coupling the current health monitor-
ing with early detection and disease interception, will have a major 
economic impact. In Europe, 20% of the population will soon be over 65, 
with an age distribution that will continue to change until 12% are over 
80 in 208066. Given the prevalence and cost of caring for people with 
degenerative conditions and the increase in chronic lifestyle-induced 
diseases, the knowledge and technologies developed by LifeTime will 
allow us to detect them earlier, and avoid their worst manifestations. 
LifeTime would also have an impact in the era of unexpected pandemics 
such as COVID-19 by rapidly determining the cellular and molecular 
basis of the disease. This would identify potential therapeutic strategies 
for patient subgroups as well as starting point for the development of 
new efficient therapies.
One of healthcare’s largest outstanding issues is that many patients 
do not respond to commonly prescribed treatments. Whereas 
well-controlled randomised clinical trials provide evidence for sta-
tistical utility of a given therapy, in actual practice often many patients 
must be treated before a single patient will show a measurable benefit. 
Other patients may not benefit at all or even be harmed67 leading to 
an economic loss that is estimated to be in the hundreds of billions 
€/year. The variable therapeutic responses originating from the cellu-
lar and genetic heterogeneity that exists in cancer and other complex 
diseases, contributes not only to the failure of treatments, but also to 
the rising cost of drug development, which is currently estimated at 
~€1-2 billion per drug. In silico models for disease trajectories gener-
ated by LifeTime will enable the integration of personal genetic and 
lifestyle information into predictive models of disease course. This 
will allow physicians to determine and implement optimal therapeu-
tic strategies tailored to the individual (precision medicine) with 
sophisticated timing of disease interception. The knowledge gained 
will also contribute to a more appropriate selection of patients for 
clinical trials.
Outlook Summary
Recent advances in key single-cell technologies, AI and patient-based 
experimental systems, such as iPS and organoids, have set the stage for 
their integration and deployment to improve mechanistic molecular 
understanding, prediction, and treatment of disease onset and progres-
sion. Patients will benefit from cell-based medicine though the earlier 
detection of diseases at a stage where they can be effectively inter-
cepted. The novel, integrated technologies will enable the selection, 
monitoring and, if necessary, modification of therapeutic strategies for 
an individual to improve clinical outcomes based on high-resolution 
cellular information. Within the next decade, the obtained molecular 
mechanistic information has the potential to revolutionise drug discov-
ery processes, clinical trial design, and eventually be incorporated into 
clinicians’ daily decision-making processes. As the LifeTime community 
continues to grow, new individuals, institutions and companies are 
encouraged to join and contribute to establishing a European platform 
to implement single-cell and data-driven medicine to address the grow-
ing burden of complex and chronic diseases.
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Fig. 1 | Early disease detection and interception by understanding and 
targeting cellular trajectories through time. (A) Cells are programmed to 
develop and differentiate along many different specific lineage trajectories 
(blue trajectories) to finally reach their functional state. When these normal 
lineage processes go awry, it can cause a cell to deviate from a healthy state and 
move towards a complex disease space (coloured manifolds defined by 
multi-dimensional molecular space – including gene expression, protein 
modifications, metabolism), as shown by red trajectories. (B) Many diseases 
are only detected at a relatively late state with the onset of symptoms (red 
trajectory) and when pathophysiological changes can be at an advanced stage 
(red cells). At this point, cells, tissues and organs have undergone extensive and 
often irreversible molecular and physiological changes since the initial events 
that caused them to deviate from a healthy state. Hence, the choice of 
interventions may be limited and often require harsh or invasive procedures. 
(C) Understanding the early molecular mechanisms that cause cells to deviate 
from a healthy to a disease trajectory will provide biomarkers for early 
detection of disease and new drug targets and innovative therapies to intercept 
diseases before onset of pathophysiology and manifestation of symptoms.
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Fig. 2 | Hallmarks of the LifeTime approach to disease interception and 
treatment. The scheme represents the development and integration of key 
technologies for investigating human diseases as envisioned by the LifeTime 
initiative. Single-cell multi-omics and imaging technologies will be developed 
for high throughput applications. Different modalities are combined to 
provide insight into underlying mechanisms based on coordinated changes 
between different regulatory molecular layers. To obtain insight into cellular 
genealogies and cellular dynamics requires the integration of lineage tracing 
tools. Technologies will also need to be scaled for deployment in the clinics. 
Integration and analysis of large, longitudinal multi-omics and imaging 
datasets will require the development of new pipelines and machine learning 
tools. These include development of causal inference and interpretative 
machine learning approaches to create molecular networks for predictive and 
multiscale disease models. Patient-derived disease models such as organoids 
will be further developed to improve tissue architecture, incorporation of 
physiological processes, such as vasculature, nerve innervation and immune 
system to provide models that more faithfully recapitulate disease processes. 
Improved knowledge of disease mechanisms requires application of 
large-scale perturbation tools to organoids. Tissue-tissue and organ-organ 
interactions will be recreated using microfluidics and organ-on-a-chip 
technologies to study key systemic interactions in diseases.
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Fig. 3 | Exploiting the LifeTime dimension to empower disease targeting. 
Single-cell multi-omics analysis of patient derived samples (blood or tissue) or 
personalised disease models (e.g. organoids, experimental disease models) 
will be profiled longitudinally to cover the different disease stages. Large-scale 
multidimensional datasets will provide quantitative, digitalized information 
that will inform on the decision-making processes of cells. This will be  
analysed using AI/machine learning to arrive at predictive models for disease 
trajectories providing single cell resolution and molecular mechanisms of 
disease onset and progression. Models will be validated using large-scale 
perturbation analysis and targeted functional studies in disease models, which 
will be used in an iterative process to improve both computational and disease 
models.
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Fig. 4 | Blueprint of the LifeTime Initiative. LifeTime proposes a large-scale 
research initiative to coordinate national efforts, as well as foster collaboration 
and knowledge exchange between the public and private sector. LifeTime 
recommends the implementation of several programmes. (1) Network of Cell 
Centres to support the European Community. A network of interdisciplinary 
centres would complement each other’s strengths and expertise in the three 
LifeTime technology areas and operate in tight association with hospitals, and 
integrate technology development with clinical practice. The connected but 
geographically distributed nodes would serve both as innovation hubs  
with strong links to industry as well as open education and training centres. 
Community coordination would avoid duplication of efforts and increase 
effectiveness requires funding instruments for a central coordination body  
(2) LifeTime research and technology integration programme, including  
both technology development and integration as well as discovering disease 
mechanisms and clinical applications. (3) Medical and biological data 
management platform. (4) Programmes fostering industry and innovation.  
(5) Education and training. (6) Ethics and societal engagement.
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